Format

Send to

Choose Destination
Br J Cancer. 2008 Jun 17;98(12):1959-65. doi: 10.1038/sj.bjc.6604387. Epub 2008 May 27.

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients.

Author information

1
Institute of Pharmacy, Department of Clinical Pharmacy, University of Bonn, Bonn, Germany.

Abstract

In this study, we investigated the kinetics of oxaliplatin-DNA adduct formation in white blood cells of cancer patients in relation to efficacy as well as oxaliplatin-associated neurotoxicity. Thirty-seven patients with various solid tumours received 130 mg m(-2) oxaliplatin as a 2-h infusion. Oxaliplatin-DNA adduct levels were measured in the first cycle using adsorptive stripping voltammetry. Platinum concentrations were measured in ultrafiltrate and plasma using a validated flameless atomic absorption spectrometry method. DNA adduct levels showed a characteristic time course, but were not correlated to platinum pharmacokinetics and varied considerably among individuals. In patients showing tumour response, adduct levels after 24 and 48 h were significantly higher than in nonresponders. Oxaliplatin-induced neurotoxicity was more pronounced but was not significantly different in patients with high adduct levels. The potential of oxaliplatin-DNA adduct measurements as pharmacodynamic end point should be further investigated in future trials.

PMID:
18506148
PMCID:
PMC2441951
DOI:
10.1038/sj.bjc.6604387
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center